In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.
In this single-centre, open-label, monocenter study, the investigators will enroll 20 patients with resectable cancer of the stomach of GEJunction. All patients will be treated with 1 cycle of atezolizumab monotherapy, followed by 4 cycles of combinationtherapy of atezolizumab, capecitabine, oxaliplatin and docetaxel, followed by surgery.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
atezolizumab 1200 mg 5 cycles
capecitabine 850 mg /m2 4 cycles
oxaliplatin 100 mg/m2 4 cycles
Marieke van de Belt
Amsterdam, Netherlands
Catharina ziekenhuis
Eindhoven, Netherlands
Incidence of adverse events following treatment (safety)
Adverse events will be assessed (according to CTC-AE v4.0) during treatment
Time frame: until 100 days after last patient last study drug treatment
pathological tumor regression grade
determined using the Mandard tumor regression grading system
Time frame: Within 6 months after last patient inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
docetaxel 50 mg/m2 4 cycles